{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026736","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.617079+00:00","generated_at":"2026-06-21T02:26:53.142236+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Assembly Biosciences reports promising interim results for HBV core inhibitors 3733 and 4334","bullets":["ABI-H3733 50 mg cohort: 6 of 8 HBV patients reached HBV DNA <LLOQ by day 21; mean 3.1 log decline.","No serious adverse events or significant ALT elevations observed in either study.","ABI-4334 30 mg single-dose showed 24-hour half-life supporting once-daily oral dosing; PK suggests high potency.","100 mg cohorts ongoing for both studies; further data expected in Q1 2023.","ABI-H3733 25 mg cohort enrolled; initial 5 patients showed mean HBV DNA reduction of ~1.9 logs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026736","json":"https://secwatch.observer/filing/0000950170-22-026736.json","markdown":"https://secwatch.observer/filing/0000950170-22-026736.md","text":"https://secwatch.observer/filing/0000950170-22-026736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026736/0000950170-22-026736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026736/asmb-20221219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:26:53.142236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}